448 related articles for article (PubMed ID: 29163050)
21. Current Strategies to Combat Cisplatin-Induced Ototoxicity.
Yu D; Gu J; Chen Y; Kang W; Wang X; Wu H
Front Pharmacol; 2020; 11():999. PubMed ID: 32719605
[TBL] [Abstract][Full Text] [Related]
22. siRNA-mediated knock-down of NOX3: therapy for hearing loss?
Rybak LP; Mukherjea D; Jajoo S; Kaur T; Ramkumar V
Cell Mol Life Sci; 2012 Jul; 69(14):2429-34. PubMed ID: 22562580
[TBL] [Abstract][Full Text] [Related]
23. Regulator of G protein signaling 17 represents a novel target for treating cisplatin induced hearing loss.
Dhukhwa A; Al Aameri RFH; Sheth S; Mukherjea D; Rybak L; Ramkumar V
Sci Rep; 2021 Apr; 11(1):8116. PubMed ID: 33854102
[TBL] [Abstract][Full Text] [Related]
24. Mutations in Cockayne Syndrome-Associated Genes (Csa and Csb) Predispose to Cisplatin-Induced Hearing Loss in Mice.
Rainey RN; Ng SY; Llamas J; van der Horst GT; Segil N
J Neurosci; 2016 Apr; 36(17):4758-70. PubMed ID: 27122034
[TBL] [Abstract][Full Text] [Related]
25. Mechanisms of cisplatin ototoxicity and progress in otoprotection.
Rybak LP
Curr Opin Otolaryngol Head Neck Surg; 2007 Oct; 15(5):364-9. PubMed ID: 17823555
[TBL] [Abstract][Full Text] [Related]
26. Evaluating protective and therapeutic effects of alpha-lipoic acid on cisplatin-induced ototoxicity.
Kim KH; Lee B; Kim YR; Kim MA; Ryu N; Jung DJ; Kim UK; Baek JI; Lee KY
Cell Death Dis; 2018 Aug; 9(8):827. PubMed ID: 30068942
[TBL] [Abstract][Full Text] [Related]
27. Mechanisms of cisplatin-induced ototoxicity and prevention.
Rybak LP; Whitworth CA; Mukherjea D; Ramkumar V
Hear Res; 2007 Apr; 226(1-2):157-67. PubMed ID: 17113254
[TBL] [Abstract][Full Text] [Related]
28. Oral Administration of Caffeine Exacerbates Cisplatin-Induced Hearing Loss.
Sheth S; Sheehan K; Dhukhwa A; Al Aameri RFH; Mamillapalli C; Mukherjea D; Rybak LP; Ramkumar V
Sci Rep; 2019 Jul; 9(1):9571. PubMed ID: 31267026
[TBL] [Abstract][Full Text] [Related]
29. Fursultiamine Prevents Drug-Induced Ototoxicity by Reducing Accumulation of Reactive Oxygen Species in Mouse Cochlea.
Kim YR; Kwon TJ; Kim UK; Lee IK; Lee KY; Baek JI
Antioxidants (Basel); 2021 Sep; 10(10):. PubMed ID: 34679662
[TBL] [Abstract][Full Text] [Related]
30. Cisplatin-induced ototoxicity: transporters playing a role in cisplatin toxicity.
Waissbluth S; Daniel SJ
Hear Res; 2013 May; 299():37-45. PubMed ID: 23467171
[TBL] [Abstract][Full Text] [Related]
31. The injured cochlea as a target for inflammatory processes, initiation of cell death pathways and application of related otoprotectives strategies.
Abi-Hachem RN; Zine A; Van De Water TR
Recent Pat CNS Drug Discov; 2010 Jun; 5(2):147-63. PubMed ID: 20167005
[TBL] [Abstract][Full Text] [Related]
32. The Role of the Reactive Oxygen Species Scavenger Agent, Astaxanthin, in the Protection of Cisplatin-Treated Patients Against Hearing Loss.
Nan B; Gu X; Huang X
Drug Des Devel Ther; 2019; 13():4291-4303. PubMed ID: 31908415
[TBL] [Abstract][Full Text] [Related]
33. Up-regulation of adenosine receptors in the cochlea by cisplatin.
Ford MS; Nie Z; Whitworth C; Rybak LP; Ramkumar V
Hear Res; 1997 Sep; 111(1-2):143-52. PubMed ID: 9307320
[TBL] [Abstract][Full Text] [Related]
34. Ototoxicity: mechanisms of cochlear impairment and its prevention.
Tabuchi K; Nishimura B; Nakamagoe M; Hayashi K; Nakayama M; Hara A
Curr Med Chem; 2011; 18(31):4866-71. PubMed ID: 21919841
[TBL] [Abstract][Full Text] [Related]
35. Sphingosine 1-phosphate receptor 2 (S1P2) attenuates reactive oxygen species formation and inhibits cell death: implications for otoprotective therapy.
Herr DR; Reolo MJ; Peh YX; Wang W; Lee CW; Rivera R; Paterson IC; Chun J
Sci Rep; 2016 Apr; 6():24541. PubMed ID: 27080739
[TBL] [Abstract][Full Text] [Related]
36. Use of zebrafish larvae lateral line to study protection against cisplatin-induced ototoxicity: A scoping review.
Domarecka E; Skarzynska M; Szczepek AJ; Hatzopoulos S
Int J Immunopathol Pharmacol; 2020; 34():2058738420959554. PubMed ID: 33084473
[TBL] [Abstract][Full Text] [Related]
37. Cisplatin ototoxicity and otoprotection with sodium salicylate.
Hyppolito MA; de Oliveira JA; Rossato M
Eur Arch Otorhinolaryngol; 2006 Sep; 263(9):798-803. PubMed ID: 16758221
[TBL] [Abstract][Full Text] [Related]
38. A novel synthetic compound, 3-amino-3-(4-fluoro-phenyl)-1H-quinoline-2,4-dione, inhibits cisplatin-induced hearing loss by the suppression of reactive oxygen species: in vitro and in vivo study.
Shin YS; Song SJ; Kang SU; Hwang HS; Choi JW; Lee BH; Jung YS; Kim CH
Neuroscience; 2013 Mar; 232():1-12. PubMed ID: 23246618
[TBL] [Abstract][Full Text] [Related]
39. Nrf2 activation protects auditory hair cells from cisplatin-induced ototoxicity independent on mitochondrial ROS production.
Zhang W; Xiong H; Pang J; Su Z; Lai L; Lin H; Jian B; He W; Yang H; Zheng Y
Toxicol Lett; 2020 Oct; 331():1-10. PubMed ID: 32428544
[TBL] [Abstract][Full Text] [Related]
40. Targeting nitrative stress for attenuating cisplatin-induced downregulation of cochlear LIM domain only 4 and ototoxicity.
Jamesdaniel S; Rathinam R; Neumann WL
Redox Biol; 2016 Dec; 10():257-265. PubMed ID: 27821327
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
